JMP reiterates Human Genome at market outperform

JMP Securities analyst Charles C. Duncan reiterated Human Genome Sciences, Inc. at market outperform after the company announced a worldwide licensing agreement with Novartis to develop and commercialize Albuferon, which includes a $45 million upfront payment and the possibility of $507.5 million in milestone payments. Shares of the Rockville, Md.-based biopharmaceutical company were up 1 cent, or 0.09%, at $10.61 on volume of 3,913,151 shares versus the three-month running average of 3,527,550 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.